These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 7663310)
41. The relationship between employer health insurance characteristics and the provision of employee assistance programs. Zarkin GA; Garfinkel SA Inquiry; 1994; 31(1):102-14. PubMed ID: 8168905 [TBL] [Abstract][Full Text] [Related]
42. Occupational medicine in the eighties: decade of change. Gibson RL Occup Med; 1988; 3(3):391-408. PubMed ID: 3043731 [TBL] [Abstract][Full Text] [Related]
44. Psychoses and illicit drug use: need for cross-cultural studies. Thirthalli J; Venkatesh BK; Gangadhar BN Acta Psychiatr Scand; 2008 Jul; 118(1):86; author reply 86-7. PubMed ID: 18489616 [No Abstract] [Full Text] [Related]
45. Having a health program isn't enough; programs must be monitored. Chenoweth D Occup Health Saf; 1986 Jun; 55(6):42-3. PubMed ID: 3737090 [No Abstract] [Full Text] [Related]
46. Just say 'No'. Policies, procedures, and legal considerations for maintaining a drug-free work-place environment. Slogoff RJ Provider; 1998 Jan; 24(1):49-50. PubMed ID: 10175136 [No Abstract] [Full Text] [Related]
48. Testing for drugs of abuse in urine. Turk J Mo Med; 1989 Jun; 86(6):337-40. PubMed ID: 2755453 [TBL] [Abstract][Full Text] [Related]
49. Anti-drug abuse effort targets the workplace. Pa Med; 1994 Jun; 97(6):33. PubMed ID: 8065782 [No Abstract] [Full Text] [Related]
50. Corporate wellness programs can be cost-effective. Dionne ED Natl Saf News; 1984 Mar; 129(3):70-2. PubMed ID: 10310479 [No Abstract] [Full Text] [Related]
51. Commentary: NIDA's role in applied research. DuPont R; Jaffe J; Kleber H NIDA Res Monogr; 1990; 100():225-39. PubMed ID: 2132773 [No Abstract] [Full Text] [Related]
52. Coke and smack at the drugstore: harm reductive drug legalization: an alternative to a criminalization society. Mamber N Cornell J Law Public Policy; 2006; 15(3):619-64. PubMed ID: 17593583 [No Abstract] [Full Text] [Related]
53. Occupational health and safety in national development--the case of Australia. Emmett EA Scand J Work Environ Health; 1997 Oct; 23(5):325-33. PubMed ID: 9403462 [TBL] [Abstract][Full Text] [Related]
54. Testing for drugs of abuse in children and adolescents. American Academy of Pediatrics Committee on Substance Abuse. Pediatrics; 1996 Aug; 98(2 Pt 1):305-7. PubMed ID: 8692638 [TBL] [Abstract][Full Text] [Related]
56. Reducing drug-related harm: Australia leads the way. Caldicott DG; Duff C Med J Aust; 2005 Feb; 182(3):140; author reply 141. PubMed ID: 15698366 [No Abstract] [Full Text] [Related]
57. Prevention: is there value for corporate purchasers? Kerr VE Am J Health Promot; 2001; 15(5):360-1. PubMed ID: 11502019 [No Abstract] [Full Text] [Related]
58. Drugs in the workplace. Rhodes D Occup Health Saf; 1998 Oct; 67(10):136-8. PubMed ID: 9772758 [No Abstract] [Full Text] [Related]
59. Is a wellness incentive money well spent? Atkinson W Bus Health; 2001 May; 19(5):23-7. PubMed ID: 11411389 [No Abstract] [Full Text] [Related]
60. The role of the EAP in the identification and treatment of substance abuse. Kramer RM Clin Lab Med; 1998 Dec; 18(4):747-53, x. PubMed ID: 9891612 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]